BCM
ANRO icon

Bridgeway Capital Management’s Alto Neuroscience ANRO Stock Holding History

Bridgeway Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.18M Sell
52,653
-25,000
-32% -$463K 0.02% 675
2025
Q4 		$1.38M Hold
77,653
– – 0.03% 637
2025
Q3 		$312K Buy
77,653
+23,553
+44% +$78.1K 0.01% 915
2025
Q2 		$119K Buy
54,100
+25,000
+86% +$59.5K ﹤0.01% 1045
2025
Q1 		$62.9K Buy
+29,100
New +$104K ﹤0.01% 1103

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bridgeway Capital Management's ANRO Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Alto Neuroscience (ANRO) stake by 32% in Q1 2026, selling an estimated $463K and leaving 52,653 shares worth $1.18M. The position accounts for 0.02% of the portfolio, ranked #675.

Bridgeway Capital Management first reported a position in ANRO in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.38M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Bridgeway Capital Management held 52,653 shares of Alto Neuroscience worth $1.18M as of Q1 2026.
  • Bridgeway Capital Management sold 25,000 Alto Neuroscience shares in Q1 2026, an estimated $463K.
  • Alto Neuroscience made up 0.02% of Bridgeway Capital Management's portfolio in Q1 2026, its #675 holding.
  • Bridgeway Capital Management first reported a position in Alto Neuroscience in Q1 2025 and has held it in 5 quarters since.
  • Bridgeway Capital Management's Alto Neuroscience position peaked at $1.38M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.